Approval · Notice of Compliance 18352 · 2016
FORXIGA: Notice of Compliance 18352
Issued August 10, 2016
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 18352
- Date
- August 10, 2016
- Company
- Astrazeneca Canada IncMississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Update to the product monograph in response to an advisement letter issued april 15, 2016
Products in this notice
Medicinal ingredients
- DAPAGLIFLOZIN 5 MG per TAB
- DAPAGLIFLOZIN 10 MG per TAB